Bionomics IPO Presentation Deck

Phase 2 Trial of BNC210 in Adults with Post-Traumatic Stress Disorder (PTSD) restore 34 Multi-center, randomized, double-blind, placebo-controlled BNC210 150 mg, 300 mg, 600 mg and placebo (1:1:1:1) (liquid suspension formulation taken twice daily, b.i.d.) 12-week treatment period Bionomics i Study Design Key Selection Criteria Key Study Objectives • 193 participants 20 US sites/6 Australian sites Current diagnosis of PTSD as defined by CAPS-5 (Clinician- Administered PTSD Scale for DSM-5) • To assess the effects of BNC210 on investigator-rated symptoms of PTSD measured by CAPS-5 1 To assess the safety and tolerability of BNC210 in subjects with PTSD

View entire presentation